Conference of the Nephropathy Committee of the Argentine Diabetes Society. Part 2

Authors

  • Alicia Elbert Center for Renal Diseases and Arterial Hypertension (CEREHA S.A.), Autonomous City of Buenos Aires, Argentina
  • María Florencia Aranguren Hospital de Clínicas José de San Martín, Autonomous City of Buenos Aires, Argentina
  • Bárbara Arinovich Cabildo and Céspedes Private Clinics, Autonomous City of Buenos Aires, Argentina
  • Teresa Bensusan Cepem Medical Center, Morón, Province of Buenos Aires, Argentina
  • Fabiana Dávila Austral University Hospital, Pilar, Province of Buenos Aires, Argentina
  • Guillermo DŽMarziani Center for Renal Diseases and Arterial Hypertension (CEREHA S.A.), Province of Buenos Aires, Argentina
  • Guillermo Dieuzeide University of Buenos Aires (UBA), Nuestra Señora del Carmen Hospital, Chacabuco, Province of Buenos Aires, Argentina
  • Natalia Lueje Antonio Cetrángolo Hospital, Province of Buenos Aires, Argentina
  • Gabriela Medek Medical Scientific Laison Novo Nordisk, Vicente López, Buenos Aires, Finochietto Sanatorium Diabetes Office, Autonomous City of Buenos Aires, Argentina
  • Estrella Menéndez "Norberto Quirno" Medical Education and Clinical Research Center (CEMIC), Autonomous City of Buenos Aires, Argentina
  • Emilio Nader Endocrinologist, specialized in Diabetes, Tucumán, Argentina
  • Liliana Miriam Obregon Single Coordinating Center for Ablation and Implantation of the Province of Buenos Aires (CUCAIBA-CRAI Sur-HIGA), General Hospital San Martin de La Plata, Province of Buenos Aires, Argentina
  • María Jimena Soutelo Churruca Visca Hospital, Autonomous City of Buenos Aires, Argentina
  • Fabiana Vázquez British Hospital, Vicente López headquarters, Province of Buenos Aires, Argentina
  • Mariela Volta University of Buenos Aires (UBA), Autonomous City of Buenos Aires, Argentina
  • Yanina Castaño CETRO Dialysis Center (Olavarría Renal Studies and Treatment Center), Province of Buenos Aires, Argentina

DOI:

https://doi.org/10.47196/diab.v56i3.665

Keywords:

diabetes mellitus, chronic kidney disease, electrolyte disturbances, mineral bone metabolism, diet

Abstract

In patients with diabetes mellitus (DM) and chronic kidney disease (CKD), electrolyte and metabolic alterations constitute a real challenge. In November 2021, the Nephropathy Committee of the Argentine Diabetes Society held a scientific conference with the aim of updating hydroelectrolytic and mineral bone metabolism disorders, and dietary considerations in CKD and DM.

Author Biographies

Alicia Elbert, Center for Renal Diseases and Arterial Hypertension (CEREHA S.A.), Autonomous City of Buenos Aires, Argentina

Medical specialist in Nephrology, specialized in Diabetes; Director of the CEREHA S.A.

María Florencia Aranguren, Hospital de Clínicas José de San Martín, Autonomous City of Buenos Aires, Argentina

Medical specialist in Internal Medicine, specialized in Diabetes

Bárbara Arinovich, Cabildo and Céspedes Private Clinics, Autonomous City of Buenos Aires, Argentina

Physician specialized in Internal Medicine and Nutrition

Teresa Bensusan, Cepem Medical Center, Morón, Province of Buenos Aires, Argentina

Physician specialized in Internal Medicine, specialized in Diabetes

Fabiana Dávila, Austral University Hospital, Pilar, Province of Buenos Aires, Argentina

Medical specialist in Nutrition, Diabetes Service

Guillermo DŽMarziani, Center for Renal Diseases and Arterial Hypertension (CEREHA S.A.), Province of Buenos Aires, Argentina

Medical specialist in Internal Medicine, specialist in Nephrology and Magister in Diabetes

Guillermo Dieuzeide, University of Buenos Aires (UBA), Nuestra Señora del Carmen Hospital, Chacabuco, Province of Buenos Aires, Argentina

Doctor of Medicine, UBA, specialist in Endocrinology; Head of the Endocrinology and Diabetes Service, Nuestra Señora del Carmen Hospital

Natalia Lueje, Antonio Cetrángolo Hospital, Province of Buenos Aires, Argentina

Clinical Physician, specialist in Nutrition; Staff Physician

Gabriela Medek, Medical Scientific Laison Novo Nordisk, Vicente López, Buenos Aires, Finochietto Sanatorium Diabetes Office, Autonomous City of Buenos Aires, Argentina

Internal Medicine specialist, specialized in Diabetes

Estrella Menéndez, "Norberto Quirno" Medical Education and Clinical Research Center (CEMIC), Autonomous City of Buenos Aires, Argentina

Medical specialist in Nutrition, Nutrition and Diabetes Service

Emilio Nader, Endocrinologist, specialized in Diabetes, Tucumán, Argentina

Endocrinologist, specialized in Diabetes

Liliana Miriam Obregon, Single Coordinating Center for Ablation and Implantation of the Province of Buenos Aires (CUCAIBA-CRAI Sur-HIGA), General Hospital San Martin de La Plata, Province of Buenos Aires, Argentina

Medical specialist; Consultant in Endocrinology; Head of the Renal Transplant Area, CUCAIBA-CRAI Sur-HIGA, General Hospital San Martin de La Plata

María Jimena Soutelo, Churruca Visca Hospital, Autonomous City of Buenos Aires, Argentina

Specialist in Endocrinology, Endocrinology Service

Fabiana Vázquez, British Hospital, Vicente López headquarters, Province of Buenos Aires, Argentina

Physician specialized in Nutrition, specialized in Diabetes, Endocrinology Service

Mariela Volta, University of Buenos Aires (UBA), Autonomous City of Buenos Aires, Argentina

Bachelor of Nutrition

Yanina Castaño, CETRO Dialysis Center (Olavarría Renal Studies and Treatment Center), Province of Buenos Aires, Argentina

Medical specialist in Nutrition, Magister in Diabetes; Coordinator of the Diabetes Area

References

I. Mena-Sánchez G, Babio N, Becerra-Tomás N, Martínez-González MÁ, Díaz-López A, Corella D, et al. Association between dairy product consumption and hyperuricemia in an elderly population with metabolic syndrome. Nutr Metab Cardiovasc Dis 2020;30(2):214-222.

II. Ramírez-Sandoval JC, Madero M. Treatment of hyperuricemia in chronic kidney disease. Contrib Nephrol 2018;192:135-146.

III. Johnson RJ, Bakris GL, Borghi C, Chonchol MB, Feldman D, Lanaspa MA, et al. Hyperuricemia, acute and chronic kidney disease, hypertension, and cardiovascular disease: report of a scientific workshop organized by the National Kidney Foundation. Am J Kidney Dis 2018;71(6):851-865.

IV. Xu L, Shi Y, Zhuang S, Liu N. Recent advances on uric acid transporters. Oncotarget 2017;8(59):100852-100862.

V. Li L, Zhang Y, Zeng C. Update on the epidemiology, genetics, and therapeutic options of hyperuricemia. Am J Transl Res 2020;12(7):3167-3181.

VI. Kielstein JT, Pontremoli R, Burnier M. Management of hyperuricemia in patients with chronic kidney disease: a focus on renal protection. Current Hypertension Reports 2020;22:102. doi: 10.1007/s11906-020-01116-3.

VII. Gliozzi M, Malara N, Muscoli S, Mollace V. The treatment of hyperuricemia. International Journal of Cardiology 2016;213:23-27.

VIII. Yipa K, Cohena RE, Pillingera MH. Asymptomatic hyperuricemia: is it really asymptomatic? Curr Opin Rheumatol 2020;32:71-79.

IX. Badve SV, Pascoe EM, Tiku A, Boudville N, Brown FG, Cass A, et al. Effects of allopurinol on the progression of chronic kidney disease. N Engl J Med 2020;382:2504-13.

X. Hovind P, Rossing P, Tarnow L, Johnson RJ, Parving HH. Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes: an inception cohort study. Diabetes 2009;58:1668-1671.

XI. Pacilli A, Viazzi F, Fioretto P, Giorda C, Ceriello A, Genovese S, Russo G, Guida P, Pontremoli R, De Cosmo S; AMD-Annals Study Group. Epidemiology of diabetic kidney disease in adult patients with T1D in Italy. Diabetes Metab Res Rev 2017;33(4).

XII. Zoppini G, Targher G, Chonchol M, Ortalda V, Abaterusso C, Pichiri I, Negri C, Bonora E. Serum uric acid levels and incident chronic kidney disease in patients with type 2 diabetes and preserved kidney function. Diabetes Care 2012;35:99-104.

XIII. Hayashino Y, Okamura S, Tsujii S, Ishii H. Association of serum uric acid levels with the risk of development or progression of albuminuria among Japanese patients with type 2 diabetes. Acta Diabetol 2016;53:599-607.

XIV. Choi HK, Ford ES. Haemoglobin A1c, fasting glucose, serum C-peptide and insulin resistance in relation to serum uric acid levels. The Third National Health and Nutrition Examination Survey. Rheumatology 2008;47:713-717.

XV. Krishnan E, Pandya BJ, Chung L, Hariri A, Dabbous O. Hyperuricemia in young adults and risk of insulin resistance, prediabetes, and diabetes: a 15-year follow-up study. Am J Epidemiol 2012;176(2):108-116.

XVI. Johnson RJ, Pérez-Pozo SE, Sautin YY, Manitius J, Sánchez-Lozada LG, Feig DI, Shafiu M, Segal M, Glassock RJ, Shimada M, Roncal C, Nakagawa T. Hypothesis: could excessive fructose intake and uric acid cause type 2 diabetes? Endocrine Reviews 2009;(30):96-116.

XVII. Chen J, Liu Y, Guo H, Wang B, Sun Z, Yu J. Urine glucose excretion attenuates the association between lipid accumulation product and serum uric acid in subjects with prediabetes. Diabetes, metabolic syndrome and obesity. Targets and Therapy 2020;(13): 2297-2305.

XVIII. Valsaraj R, Singh AK, Gangopadhyay KK, Ghoshdastidar BT, Goyal G, Batin M. Management of asymptomatic hyperuricemia: Integrated Diabetes & Endocrine Academy (IDEA) consensus statement. Diabetes & Metabolic Syndrome: Clinical Research &Reviews 2020;14: 93e100.

XIX. Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, et al. 2012 American College of Rheumatology Guidelines for Management of Gout. Part 1: Systematic non pharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care & Research 2012; 64(10):1431-1446.

XX. Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castañeda-Sanabria J, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis 2017;76:29-42.

XXI. Hisatome I, Ichida K, Mineo I, Ohtahara A, Ogino K, Kuwabara M, et al. Japanese Society of Gout and Uric & Nucleic Acids 2019 Guidelines for Management of Hyperuricemia and Gout. Gout and Uric & Nucleic Acids 2020;44 (Supp).

XXII. Doria A, Galecki AT, Spino C, Pop‑Busui R, Cherney DZ, Lingvay I. Serum urate lowering with allopurinol and kidney function in type 1 diabetes. N Engl J Med 2020; 382:2493-503.

XXIII. Voelker R. Another warning for febuxostat. JAMA 2019;321(13):1245.

Published

2023-02-04

How to Cite

Elbert, A., Aranguren, M. F., Arinovich, B., Bensusan, T., Dávila, F., DŽMarziani, G., Dieuzeide, G., Lueje, N., Medek, G., Menéndez, E., Nader, E., Obregon, L. M., Soutelo, M. J., Vázquez, F., Volta, M., & Castaño, Y. (2023). Conference of the Nephropathy Committee of the Argentine Diabetes Society. Part 2. Journal of the Argentine Society of Diabetes, 56(3), 108–120. https://doi.org/10.47196/diab.v56i3.665

Similar Articles

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 > >>